Identifying and understanding disease driver genes, such as the KRAS gene in oncogenesis, is the cornerstone of targeted therapies, particularly gene therapy. Antapodia Therapeutics pioneered the identification of a series of "Master Invadopodial Regulators (MIRs)" that drive the biogenesis and the functions of invadopodia in highly invasive cancer cells. Notably, MIRs are predominantly expressed in malignant cells but not normal cells, making them ideal and safe therapeutic targets (Table 1). Therefore, targeting MIRs provides a unique opportunity to block invadopodia formation and inhibit cancer aggressiveness and metastasis.

Table 1. Antapodia's invadopodia target-genes

Molecular target 



Molecular signaling

Specific expression in/on


Invadopodia and submembranouse cytosol

Invadopodia formation & oncogenic signaling

Non-canonical Wnt signaling/Wnt, Notch, Hedgehog signaling

Invasive cancer cells/stem-like cancer cells


Invadopodial surface and endoplasmic reticulum

Invadopodia signaling & functions

Src, PKC, JNK, Rho-A, Rac-1, EMT

Invasive cancer cells

MIR-03 Invadopodial surface Peri-invadopodial proteolysis MMP activation Invasive cancer cells


Figure 1. The molecular characteristics of Antapodia's invadopodia targets

Figure 1. Antapodia Nanotherapeutics’s proprietary invadopodia targets MIR-1 and MIR-2.


Designed by Justin V. Tsai in 2021

Copyright © Antapodia Therapeutics, Inc., WA, USA. All Rights Reserved.